ISG15 Protein — Interferon-Stimulated Gene 15
Overview
ISG15 (Interferon-Stimulated Gene 15) is a small ubiquitin-like modifier protein encoded by the ISG15 gene located on chromosome 1p36.33 in humans. With a molecular weight of approximately 17 kDa, ISG15 is one of the most rapidly induced interferon-stimulated proteins and serves as a critical regulator of innate immune responses and cellular stress pathways. Initially characterized as a protein induced by viral infection and interferon-β treatment, ISG15 has emerged as a significant player in neuroinflammation and the pathophysiology of neurodegenerative diseases. Unlike ubiquitin, to which it shares structural homology, ISG15 possesses two ubiquitin-like domains connected by a flexible linker region, conferring unique biochemical properties and functional capabilities.
Function/Biology
ISG15 functions primarily as a post-translational modifier through a process called ISGylation, whereby ISG15 is covalently conjugated to lysine residues on target proteins. This process requires a series of enzymatic reactions: the E1 enzyme (UBE1L) activates ISG15 in an ATP-dependent manner, the E2 enzyme (UBCH8) facilitates transfer, and E3 ligases (such as HERC5 and TRIM25) provide substrate specificity. The conjugation is reversible through deconjugation by the cysteine protease USP18, enabling dynamic regulation of ISGylated protein pools.
...ISG15 Protein — Interferon-Stimulated Gene 15
Overview
ISG15 (Interferon-Stimulated Gene 15) is a small ubiquitin-like modifier protein encoded by the ISG15 gene located on chromosome 1p36.33 in humans. With a molecular weight of approximately 17 kDa, ISG15 is one of the most rapidly induced interferon-stimulated proteins and serves as a critical regulator of innate immune responses and cellular stress pathways. Initially characterized as a protein induced by viral infection and interferon-β treatment, ISG15 has emerged as a significant player in neuroinflammation and the pathophysiology of neurodegenerative diseases. Unlike ubiquitin, to which it shares structural homology, ISG15 possesses two ubiquitin-like domains connected by a flexible linker region, conferring unique biochemical properties and functional capabilities.
Function/Biology
ISG15 functions primarily as a post-translational modifier through a process called ISGylation, whereby ISG15 is covalently conjugated to lysine residues on target proteins. This process requires a series of enzymatic reactions: the E1 enzyme (UBE1L) activates ISG15 in an ATP-dependent manner, the E2 enzyme (UBCH8) facilitates transfer, and E3 ligases (such as HERC5 and TRIM25) provide substrate specificity. The conjugation is reversible through deconjugation by the cysteine protease USP18, enabling dynamic regulation of ISGylated protein pools.
Beyond its role as a post-translational modifier, ISG15 functions as a secreted signaling molecule. Free ISG15 can be secreted and act as an interferon-like cytokine, binding to the LPS-binding protein (LBP) and potentially modulating immune responses. ISG15 also plays roles in regulating protein-protein interactions, altering protein localization, and modulating protein stability and activity. Within cells, ISG15 conjugation affects proteins involved in innate immunity, viral defense, and proteostasis.
Role in Neurodegeneration
Emerging evidence implicates ISG15 dysregulation in multiple neurodegenerative conditions. In Parkinson's disease, elevated ISG15 levels and increased ISGylation have been detected in substantia nigra tissue and cerebrospinal fluid, correlating with neuroinflammatory markers and dopaminergic neuronal loss. In Alzheimer's disease, ISG15 expression is upregulated in association with amyloid-β pathology and tau hyperphosphorylation, contributing to neuroinflammatory cascade amplification. In ALS (amyotrophic lateral sclerosis), ISG15 dysregulation has been identified in both familial and sporadic forms, with altered ISGylation patterns affecting SOD1 and other motor neuron proteins.
The chronic activation of ISG15 signaling in neurodegenerative conditions suggests that while acute ISG15 responses are protective against pathogens, sustained elevation becomes pathological, promoting excessive neuroinflammation, microglial activation, and neuronal stress.
Molecular Mechanisms
ISG15-mediated neuropathology operates through several interconnected mechanisms. ISGylation of tau protein may promote its phosphorylation and aggregation, accelerating tauopathy. In the context of α-synuclein, ISG15 conjugation can alter protein conformation and promote its aggregation, exacerbating Parkinson's pathology. ISGylation of components in the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP) impairs protein degradation capacity, allowing accumulation of toxic protein aggregates. Additionally, ISG15 amplifies NF-κB and JAK-STAT signaling pathways, driving pro-inflammatory cytokine production by activated microglia and astrocytes, which secrete neurotoxic factors including TNF-α, IL-6, and IL-1β.
Clinical/Research Significance
ISG15 represents an emerging biomarker for neuroinflammatory status in neurodegenerative diseases. Elevated CSF and serum ISG15 levels correlate with disease progression in Parkinson's disease and Alzheimer's disease, suggesting potential utility in early diagnosis and disease monitoring. ISG15 pathway modulation through USP18 inhibitors or E1 enzyme blockers shows promise in preclinical models, reducing neuroinflammation and slowing neurodegeneration. Understanding ISG15 biology may facilitate development of targeted therapeutics that selectively dampen chronic ISG15 signaling while preserving its acute antiviral functions.
- Ubiquitin and ubiquitin-like proteins: SUMO, ubiquitin
- Interferon signaling: Interferon-β, JAK-STAT pathway, NF-κB
- E3 ligases: HERC5, TRIM25, TRIM6
- Deconjugases: USP18
- Associated pathologies: α-synuclein, tau protein, TDP-43
- **Neuroin